Aug 2026· International Journal of Nanomedicine· Vol 21, pp. 1-18· 0 citations· 117 references
Medicine
TL;DR
Overall, this review highlights the current progress, remaining challenges, and future perspectives of PEG-PLGA nanoparticles for targeted and immune-based therapies in NSCLC.
Abstract
Abstract PEGylated poly(lactic-co-glycolic acid) (PEG-PLGA) nanoparticles have attracted increasing attention as a versatile and biocompatible nanoplatform for non-small cell lung cancer (NSCLC) therapy. Benefiting from prolonged circulation time, controllable drug-release behavior, and flexible surface modification, PEG-PLGA nanocarriers can effectively enhance tumor accumulation while reducing systemic toxicity. Recent advances indicate that PEG-PLGA nanoparticles not only improve the delivery efficiency of chemotherapeutic agents but also enable active tumor targeting through ligand conjugation and contribute to the regulation of the tumor immune microenvironment. In particular, these nanoplatforms have shown promising potential in enhancing antigen presentation, alleviating immunosuppression, and synergizing with immunotherapeutic strategies such as immune checkpoint blockade. Nevertheless, several challenges remain for clinical translation, including large-scale manufacturing, formulation reproducibility, and regulatory considerations. Overall, this review highlights the current progress, remaining challenges, and future perspectives of PEG-PLGA nanoparticles for targeted and immune-based therapies in NSCLC.
Pediatric brain tumors continue to be one of the leading causes of death among children due to cancer because of the inadequacies of existing treatments, which include poor tumor selectivity, poor permeability across the blood-brain barrier, resistance to treatment, and high levels of side effects on developing tissu...
PEGylation has been shown to extend the circulatory lifetime, enhance drug deposition in tumors, and minimize off-target toxicity, and more effective design solutions should be employed, including stimuli-responsive liposomes and patient-tailored methods.
Ashish Kumar, Md Moidul Islam, Moidul Islam Judder et al.· Recent Advances in Drug Deli...· 0 citations
In vitro and in vivo studies further demonstrated the potential of this nanoparticle system for controlled, targeted, and biocompatible delivery of anticancer agents.
Madhusudan Maity, Niranjan Panda, Subas C. Dinda et al.· Recent Patents on Nanotechno...· 0 citations
Breast cancer remains a major global health concern, highlighting the need for advanced drug delivery strategies that can improve therapeutic efficacy while minimizing systemic toxicity. Although several reviews have discussed polymeric nanocarriers for breast cancer therapy, many have primarily focused on specific p...
Nazanin Amiryaghoubi, B. Kim· ACS Applied Nano Materials· 0 citations
The biodegradable nanomaterials exhibit promising potential for tumor immunotherapy due to their unique advantages including biodegradability, simple and cost-effective synthesis, and use of renewable resources, aligning with environmental and sustainable development goals.
Ru-Tuan Dong, Shuai-Shuai Ding, Bo-Kai Song et al.· Journal of materials chemist...· 1 citation
Overall, this review provides a comprehensive overview of the design, synthesis, functionalization, therapeutic applications, pharmacokinetics, biodistribution, safety profiles, and clinical translation potential of folate-functionalized chitosan NPs for precision cancer therapy.
Mohammad Sameer Khan, W. Almalki· Medical Oncology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.